 Connection
Thomas Campbell to CD4 Lymphocyte Count
This is a "connection" page, showing publications Thomas Campbell has written about CD4 Lymphocyte Count.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.991 |
|
|
|
-
Erlandson KM, Allshouse AA, Jankowski CM, MaWhinney S, Kohrt WM, Campbell TB. Functional impairment is associated with low bone and muscle mass among persons aging with HIV infection. J Acquir Immune Defic Syndr. 2013 Jun 01; 63(2):209-15.
Score: 0.093
-
Erlandson KM, Allshouse AA, Jankowski CM, Lee EJ, Rufner KM, Palmer BE, Wilson CC, MaWhinney S, Kohrt WM, Campbell TB. Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis. 2013 Jul 15; 208(2):249-59.
Score: 0.092
-
Safren SA, Hendriksen ES, Smeaton L, Celentano DD, Hosseinipour MC, Barnett R, Guanira J, Flanigan T, Kumarasamy N, Klingman K, Campbell T. Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world. AIDS Behav. 2012 Feb; 16(2):266-77.
Score: 0.085
-
Grinsztejn B, Smeaton L, Barnett R, Klingman K, Hakim J, Flanigan T, Kumarasamy N, Campbell T, Currier J. Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count. Antivir Ther. 2011; 16(7):1057-62.
Score: 0.078
-
Campbell TB. Are all HIV type 1 strains created equal? Clin Infect Dis. 2006 Mar 15; 42(6):853-4.
Score: 0.056
-
Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan TC, Kuritzkes DR. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis. 2005 Jul 15; 41(2):236-42.
Score: 0.053
-
Connick E, MaWhinney S, Wilson CC, Campbell TB. Challenges in the study of patients with HIV type 1 seroconversion. Clin Infect Dis. 2005 May 01; 40(9):1355-7.
Score: 0.053
-
Connick E, Kane MA, White IE, Ryder J, Campbell TB. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. Clin Infect Dis. 2004 Dec 15; 39(12):1852-5.
Score: 0.051
-
Gatechompol S, Kerr SJ, Cardoso SW, Samaneka W, Tripathy S, Godbole S, Ghate M, Kanyama C, Nyirenda M, Sugandhavesa P, Machado A, Van Leth F, Campbell TB, Swindlells S, Avihingsanon A, Cobelens F. Monocyte to lymphocyte ratio and hemoglobin level to predict tuberculosis after antiretroviral therapy initiation. AIDS. 2024 01 01; 38(1):31-38.
Score: 0.047
-
Nyirenda M, Ngongondo M, Kang M, Umbleja T, Krown SE, Godfrey C, Samaneka W, Mngqibisa R, Hoagland B, Mwelase N, Caruso S, Martinez-Maza O, Dittmer DP, Borok M, Hosseinipour MC, Campbell TB. Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early Chemotherapy. J Acquir Immune Defic Syndr. 2020 08 01; 84(4):422-429.
Score: 0.038
-
Vecchio AC, Marra CM, Schouten J, Jiang H, Kumwenda J, Supparatpinyo K, Hakim J, Sacktor N, Campbell TB, Tripathy S, Kumarasamy N, La Rosa A, Santos B, Silva MT, Kanyama C, Firnhaber C, Hosseinipour MC, Mngqibisa R, Hall C, Cinque P, Robertson K. Distal Sensory Peripheral Neuropathy in Human Immunodeficiency Virus Type 1-Positive Individuals Before and After Antiretroviral Therapy Initiation in Diverse Resource-Limited Settings. Clin Infect Dis. 2020 06 24; 71(1):158-165.
Score: 0.038
-
Campbell TB, Sevin A, Coombs RW, Peterson GC, Rosandich M, Kuritzkes DR, Mladenovic J, Landay A, Wong R, Ambruso D, Miles S, Pomerantz RJ, Schooley RT. Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team. Blood. 2000 Jan 01; 95(1):48-55.
Score: 0.037
-
Balagopal A, Asmuth DM, Yang WT, Campbell TB, Gupte N, Smeaton L, Kanyama C, Grinsztejn B, Santos B, Supparatpinyo K, Badal-Faesen S, Lama JR, Lalloo UG, Zulu F, Pawar JS, Riviere C, Kumarasamy N, Hakim J, Li XD, Pollard RB, Semba RD, Thomas DL, Bollinger RC, Gupta A. Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort Study. J Acquir Immune Defic Syndr. 2015 Oct 01; 70(2):163-71.
Score: 0.027
-
Shivakoti R, Gupte N, Yang WT, Mwelase N, Kanyama C, Tang AM, Pillay S, Samaneka W, Riviere C, Berendes S, Lama JR, Cardoso SW, Sugandhavesa P, Semba RD, Christian P, Campbell TB, Gupta A. Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy. Nutrients. 2014 Nov 13; 6(11):5061-78.
Score: 0.026
-
Zheng Y, Hughes MD, Lockman S, Benson CA, Hosseinipour MC, Campbell TB, Gulick RM, Daar ES, Sax PE, Riddler SA, Haubrich R, Salata RA, Currier JS. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens. Clin Infect Dis. 2014 Sep 15; 59(6):888-96.
Score: 0.025
-
Thio CL, Smeaton L, Saulynas M, Hwang H, Saravanan S, Saravan S, Kulkarni S, Hakim J, Nyirenda M, Iqbal HS, Lalloo UG, Mehta AS, Hollabaugh K, Campbell TB, Lockman S, Currier JS. Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. AIDS. 2013 Jan 14; 27(2):191-201.
Score: 0.023
-
Krishnan S, Schouten JT, Atkinson B, Brown T, Wohl D, McComsey GA, Glesby MJ, Shikuma C, Haubrich R, Tebas P, Campbell TB, Jacobson DL. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr. 2012 Nov 01; 61(3):381-9.
Score: 0.022
-
Tate DF, Sampat M, Harezlak J, Fiecas M, Hogan J, Dewey J, McCaffrey D, Branson D, Russell T, Conley J, Taylor M, Schifitto G, Schifitto G, Zhong J, Daar ES, Alger J, Brown M, Singer E, Campbell T, McMahon D, Tso Y, Matesan J, Letendre S, Paulose S, Gaugh M, Tripoli C, Yiannoutsos C, Bigler ED, Cohen RA, Guttmann CR, Navia B. Regional areas and widths of the midsagittal corpus callosum among HIV-infected patients on stable antiretroviral therapies. J Neurovirol. 2011 Aug; 17(4):368-79.
Score: 0.020
-
Harezlak J, Buchthal S, Taylor M, Schifitto G, Zhong J, Daar E, Alger J, Singer E, Campbell T, Yiannoutsos C, Cohen R, Navia B. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS. 2011 Mar 13; 25(5):625-33.
Score: 0.020
-
Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, Sawe F, Asmelash A, Hosseinipour MC, Mohapi L, Stringer E, Mngqibisa R, Siika A, Atwine D, Hakim J, Shaffer D, Kanyama C, Wools-Kaloustian K, Salata RA, Hogg E, Alston-Smith B, Walawander A, Purcelle-Smith E, Eshleman S, Rooney J, Rahim S, Mellors JW, Schooley RT, Currier JS. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010 Oct 14; 363(16):1499-509.
Score: 0.019
-
Letang E, Almeida JM, Miró JM, Ayala E, White IE, Carrilho C, Bastos R, Nhampossa T, Menéndez C, Campbell TB, Alonso PL, Naniche D. Predictors of immune reconstitution inflammatory syndrome-associated with kaposi sarcoma in mozambique: a prospective study. J Acquir Immune Defic Syndr. 2010 Apr; 53(5):589-97.
Score: 0.019
-
Cohen RA, Harezlak J, Schifitto G, Hana G, Clark U, Gongvatana A, Paul R, Taylor M, Thompson P, Alger J, Brown M, Zhong J, Campbell T, Singer E, Daar E, McMahon D, Tso Y, Yiannoutsos CT, Navia B. Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neurovirol. 2010 Feb; 16(1):25-32.
Score: 0.018
-
Boritz E, Rapaport EL, Campbell TB, Koeppe JR, Wilson CC. CD4+ T cell targeting of human immunodeficiency virus type 1 (HIV-1) peptide sequences present in vivo during chronic, progressive HIV-1 disease. Virology. 2007 Apr 25; 361(1):34-44.
Score: 0.015
-
Barbour JD, Hecht FM, Little SJ, Markowitz M, Daar ES, Kelleher AD, Routy JP, Campbell TB, Rosenberg ES, Segal MR, Weidler J, Grant RM. Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity. AIDS. 2006 Oct 24; 20(16):2123-5.
Score: 0.015
-
Gripshover BM, Ribaudo H, Santana J, Gerber JG, Campbell TB, Hogg E, Jarocki B, Hammer SM, Kuritzkes DR. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006; 11(5):619-23.
Score: 0.014
-
Schooley RT, Mladenovic J, Sevin A, Chiu S, Miles SA, Pomerantz RJ, Campbell TB, Bell D, Ambruso D, Wong R, Landay A, Coombs RW, Fox L, Kamoun M, Jacovini J. Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. J Infect Dis. 2000 Jan; 181(1):148-57.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|